US6503923B1 - Haloalkoxy imidazonaphthyridines - Google Patents

Haloalkoxy imidazonaphthyridines Download PDF

Info

Publication number
US6503923B1
US6503923B1 US09/926,267 US92626701A US6503923B1 US 6503923 B1 US6503923 B1 US 6503923B1 US 92626701 A US92626701 A US 92626701A US 6503923 B1 US6503923 B1 US 6503923B1
Authority
US
United States
Prior art keywords
hydrogen
alkoxy
substituents
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/926,267
Other languages
English (en)
Inventor
Jörg Senn-Bilfinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Assigned to ALTANA PHARMA AG reassignment ALTANA PHARMA AG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH
Application granted granted Critical
Publication of US6503923B1 publication Critical patent/US6503923B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Definitions

  • the invention relates to novel compounds which are used in the pharmaceutical industry as active compounds for the production of medicaments.
  • U.S. Pat. No. 4,468,400 describes tricyclic imidazo[1,2-a]pyridines having various ring systems fused to the imidazopyridine parent structure, which are intended to be suitable for the treatment of peptic ulcers.
  • International Patent Application WO98/42707 discloses tetrahydroimidazonaphthyridines having a very specific substitution pattern, which are likewise intended to be suitable for the treatment of gastric and intestinal disorders.
  • the invention relates to compounds of the formula I
  • R1 is hydrogen, 1-4C-alkyl or hydroxy-1-4C-alkyl
  • R2 is hydrogen, 1-4C-alkyl, hydroxy-1-4C-alkyl, halogen, 2-4C-alkenyl or 2-4C-alkynyl,
  • R3 is hydrogen, halogen, trifluoromethyl, 1-4C-alkyl, 2-4C-alkenyl or 2-4C-alkynyl,
  • one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy, 1-4C-alkylcarbonyloxy or the radical R4′, or in which R4a and R4b together are O (oxygen),
  • R4′ is 1-4C-alkoxy which is completely or mainly substituted by halogen
  • one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy, 1-4C-alkylcarbonyloxy or the radical R5′, or in which R5a and R5b together are O (oxygen),
  • R5′ is 1-4C-alkoxy which is completely or mainly substituted by halogen
  • one of the substituents R4a and R4b on the one hand and one of the substituents R5a and R5b on the other hand in each case is hydrogen, and the other substituents in each case together form a 1-2C-alkylenedioxy radical which is completely or partially substituted by halogen,
  • R6 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or trifluoromethyl and
  • R7 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy
  • 1-4C-alkyl represents strain-chain or branched alkyl radicals having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl, isobutyl, sec-butyl, tert-butyl, propyl, isopropyl, ethyl and methyl radical.
  • Hydroxy-1-4C-alkyl represents abovementioned 1-4C-alkyl radicals which are substituted by a hydroxyl group. Examples which may be mentioned are the hydroxymethyl, the 2-hydroxyethyl and the 3-hydroxypropyl radical.
  • Halogen within the meaning of the invention is bromine, chlorine or fluorine.
  • 2-4C-alkenyl represents straight-chain or branched alkenyl radicals having 2 to 4 carbon atoms. Examples which may be mentioned are the 2-butenyl, 3-butenyl, 1-propenyl and the 2-propenyl radical (allyl radical).
  • 2-4C-alkynyl represents straight-chain or branched alkynyl radicals having 2 to 4 carbon atoms. Examples which may be mentioned are the 2-butynyl, 3-butynyl and preferably the 2-propynyl radical (propargyl radical).
  • 1-4C-alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy, isobutoxy, sec-butoxy, tert-butoxy, propoxy, isopropoxy and preferably the ethoxy and methoxy radical.
  • 1-4C-alkoxy-1-4C-alkoxy represents one of the abovementioned 1-4C-alkoxy radicals which is substituted by a further 1-4C-alkoxy radical.
  • examples which may be mentioned are the radicals 2-methoxyethoxy (CH 3 —O—CH 2 —CH 2 —O—) and 2-ethoxyethoxy (CH 3 —CH 2 —O—CH 2 —CH 2 —O—).
  • 1-4C-alkylcarbonyl represents a radical which, in addition to the carbonyl group, contains one of the abovementioned 1-4C-alkyl radicals.
  • An example which may be mentioned is the acetyl radical.
  • 1-4C-alkylcarbonyloxy represents a 1-4C-alkylcarbonyl group which is bonded to an oxygen atom.
  • An example which may be mentioned is the acetoxy radical (CH 3 CO—O—).
  • halogen-substituted 1-4C-alkoxy which may be primarily mentioned are chlorine and/or, in particular, fluorine-substituted 1-4C-alkoxy radicals.
  • halogen-substituted 1-4C-alkoxy which may be mentioned are the 2,2,2-trichloroethoxy, the hexachloroisopropoxy, the pentachloroisopropoxy, the 1,1,1-trichloro-3,3,3-trifluoro-2-propoxy, the 1,1,1-trichloro-2-methyl-2-propoxy, the 1,1,1-trichloro-2-propoxy, the 3-bromo-1,1,1-trifluoro-2-propoxy, the 3-bromo-1,1,1-trifluoro-2-butoxy, the 4-bromo-3,3,4,4-tetrafluoro-1-butoxy, the chlorodifluoromethoxy, the 1,1,1,3,3,3-hexafluoro-2-prop
  • fluorine-substituted 1-2C-alkylenedioxy which may be mentioned in particular are fluorine-substituted 1-2C-alkylenedioxy, for example the difluoroethylenedioxy (—O—CF 2 —CH 2 —O—), the tetrafluoroethylenedioxy (—O—CF 2 —CF 2 —O—) and in particular the difluoromethylenedioxy (—O—CF 2 —O—), and the 1,1,2-trifluoroethylenedioxy radical (—O—CF 2 CHF—O—) and also the chlorotrifluoroethylenedioxy radical.
  • fluorine-substituted 1-2C-alkylenedioxy for example the difluoroethylenedioxy (—O—CF 2 —CH 2 —O—), the tetrafluoroethylenedioxy (—O—CF 2 —CF 2 —O—) and in particular the difluoromethylenedioxy (—O—CF
  • 1-4C-alkoxycarbonyl represents a carbonyl group to which one of the abovementioned 1-4C-alkoxy radicals is bonded. Examples which may be mentioned are the methoxycarbonyl (CH 3 O—C(O)—) and the ethoxycarbonyl radical (CH 3 CH 2 O—C(O)—).
  • 1-4C-alkoxycarbonylamino represents an amino radical which is substituted by one of the abovementioned 1-4C-alkoxycarbonyl radicals. Examples which may be mentioned are the ethoxycarbonylamino and the methoxycarbonylamino radical.
  • 1-4C-alkoxy-1-4C-alkoxycarbonyl represents a carbonyl group to which one of the abovementioned 1-4C-alkoxy-1-4C-alkoxy radicals is bonded.
  • Examples which may be mentioned are the 2-methoxyethoxycarbonyl(CH 3 —O—CH 2 CH 2 —O—CO—) and the 2-ethoxyethoxycarbonyl radical (CH 3 CH 2 —O—CH 2 CH 2 —O—CO—).
  • 1-4C-alkoxy-1-4C-alkoxycarbonylamino represents an amino radical which is substituted by one of the abovementioned 1-4C-alkoxy-1-4C-alkoxycarbonyl radicals. Examples which may be mentioned are the 2-methoxyethoxycarbonylamino and der 2-ethoxyethoxycarbonylamino radical.
  • Pharmacologically intolerable salts which can be initially obtained, for example, as process products in the preparation of the compounds according to the invention on the industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.
  • the compounds according to the invention and their salts can contain various amounts of solvents if they are isolated, for example, in crystalline form.
  • the invention therefore also comprises all solvates and in particular all hydrates of the compounds of the formula I, and all solvates and in particular all hydrates of the salts of the compounds of the formula I.
  • the compounds of the formula I have at least two chiral centers.
  • the invention relates to all conceivable stereoisomers in any desired mixing ratio to one another, including the pure enantiomers, which are a preferred subject of the invention.
  • An exemplary preferred radical R1 is the methyl radical.
  • Exemplary preferred radicals R2 are the methyl and the hydroxymethyl radical.
  • R3 in the context of the present invention is preferably hydrogen.
  • R1 is 1-4C-alkyl
  • R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl
  • R3 is hydrogen
  • one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical R4′,
  • R4′ is completely or mainly halogen-substituted halogen-substituted 1-4C-alkoxy, one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical R5′,
  • R5′ is completely or mainly halogen-substituted 1-4C-alkoxy
  • R5a and R5b must have the meaning R5′,
  • one of the substituents R4a and R4b on the one hand and one of the substituents R5a and R5b on the other hand is in each case hydrogen, and the other substituents in each case together form a completely or partially halogen-substituted 1-2C-alkylenedioxy radical,
  • R6 is hydrogen, halogen or trifluoromethyl
  • R7 is hydrogen or halogen
  • R1 is 1-4C-alkyl
  • R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl
  • R3 is hydrogen
  • one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical R4′,
  • R4′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or the radical R5′,
  • R5′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • R5a and R5b must have the meaning R5′,
  • one of the substituents R4a and R4b on the one hand and one of the substituents R5a and R5b on the other hand is in each case hydrogen, and the other substituents in each case together form a completely or partially fluorine-substituted 1-2C-alkylenedioxy radical or chlorotrifluoroethylenedioxy radical,
  • R6 is hydrogen, halogen or trifluoromethyl
  • R7 is hydrogen or halogen
  • one of the substituents R4a and R4b is hydrogen and the other is the radical R4′ and
  • one of the substituents R5a and R5b is hydrogen and the other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy.
  • one of the substituents R4a and R4b is hydrogen and the other is the radical R4′ and
  • one of the substituents R5a and R5b is hydrogen and the other is the radical R5′.
  • one of the substituents R4a and R4b is hydrogen and the other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy and one of the substituents R5a and R5b is hydrogen and the other is the radical R5′.
  • R1 is 1-4C-alkyl
  • R2 is 1-4C-alkyl
  • R3 is hydrogen
  • R4′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • R5′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • R6 is hydrogen
  • R7 is hydrogen
  • Preferred compounds I* of embodiment a are those in which
  • R1 is 1-4C-alkyl
  • R2 is 1-4C-alkyl
  • R3 is hydrogen
  • one of the substituents R4a and R4b is hydrogen and the other is R4′,
  • R4′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • one of the substituents R5a and R5b is hydrogen and the other is hydroxyl
  • R6 is hydrogen
  • R7 is hydrogen
  • Preferred compounds I* of embodiment b are those in which
  • R1 is 1-4C-alkyl
  • R2 is 1-4C-alkyl
  • R3 is hydrogen
  • one of the substituents R4a and R4b is hydrogen and the other is R4′,
  • R4′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • one of the substituents R5a and R5b is hydrogen and the other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy,
  • R6 is hydrogen
  • R7 is hydrogen
  • Preferred compounds I* of embodiment c are those in which
  • R1 is 1-4C-alkyl
  • R2 is 1-4C-alkyl
  • R3 is hydrogen
  • one of the substituents R4a and R4b is hydrogen and the other is R4′,
  • R4′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • one of the substituents R5a and R5b is hydrogen and the other is R5′,
  • R5′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • R6 is hydrogen
  • R7 is hydrogen
  • Preferred compounds I* of embodiment d are those in which
  • R1 is 1-4C-alkyl
  • R2 is 1-C-alkyl
  • R3 is hydrogen
  • one of the substituents R4a and R4b is hydrogen and the other is 1-4C-alkoxy or 1-4C-alkoxy-1-4C-alkoxy,
  • one of the substituents R5a and R5b is hydrogen and the other is R5′,
  • R5′ is completely or mainly fluorine-substituted 1-4C-alkoxy or chlorodifluoromethoxy
  • R6 is hydrogen
  • R7 is hydrogen
  • Selected preferred compounds I* are those of embodiments a, b, c and d in which R5b is hydrogen.
  • Selected particularly preferred compounds I* are those of embodiments a, b, c and d in which R5b is hydrogen and R4a is hydrogen.
  • Selected preferred radicals R4′ and R5′ are the 2,2,2-trifluoroethoxy- and the difluoromethoxy radical.
  • the compounds according to the invention are prepared, for example, starting from the compounds of the formula I disclosed in WO98/42707, in which at least one of the substituents R4a, R4b, R5a and R5b has the meaning hydroxyl (subsequently called “starting compounds”).
  • starting compounds the substituents R4a, R4b, R5a and R5b has the meaning hydroxyl.
  • the substances according to the invention are isolated and purified in a manner known per se, for example by distilling off the solvent in vacuo and recrystallizing the resulting residue from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on suitable support material.
  • Salts are obtained by dissolving the free compound in a suitable solvent, e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid, or to which the desired acid is then added.
  • a suitable solvent e.g. in a chlorinated hydrocarbon, such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid, or to which the desired acid is then added.
  • the salts are obtained by filtering, reprecipitating, precipitating with a nonsolvent for the addition salt or by evaporation of the solvent. Salts obtained can be converted into the free compounds, which in turn can be converted into salts, by alkalization or by acidification. In this way, pharmacologically nontolerable salts can be converted into pharmacologically tolerable salts.
  • the pure enantiomers in particular the pure enantiomers of the formula I*, which are a preferred subject of the invention, can be obtained in a manner familiar to the person skilled in the art, for example by enantioselective synthesis, by chromatographic resolution on chiral separating columns, by derivatization with chiral auxiliary reagents, subsequent separation of diastereomers and cleavage of the chiral auxiliary group, by salt formation with chiral acids, subsequent resolution of the salts and liberation of the desired compound from the salt, or by (fractional) crystallization from a suitable solvent.
  • the compounds of the formula I and their salts have valuable pharmacological properties which make them commercially utilizable. In particular, they exhibit a marked inhibition of the secretion of gastric acid and an excellent gastric and intestinal protective action in warm-blooded mammals, in particular humans.
  • the compounds according to the invention are distinguished here by a high selectivity of action, an advantageous duration of action, a particularly good enteral activity, the absence of significant side effects and a wide therapeutic breadth.
  • Gastric and intestinal protection is understood in this connection as meaning the prevention and treatment of gastrointestinal diseases, in particular gastrointestinal inflammatory diseases and lesions (such as, for example, stomach ulcer, duodenal ulcer, gastritis, functional gastropathy due to hyperacidity or medicaments), which can be caused, for example by microorganisms (e.g. Helicobacter pylori), bacterial toxins, medicaments (e.g. certain antiinflammatories and antirheumatics), chemicals, e.g. ethanol), gastric acid or stress situations.
  • gastrointestinal inflammatory diseases and lesions such as, for example, stomach ulcer, duodenal ulcer, gastritis, functional gastropathy due to hyperacidity or medicaments
  • microorganisms e.g. Helicobacter pylori
  • bacterial toxins e.g. certain antiinflammatories and antirheumatics
  • chemicals e.g. ethanol
  • the compounds according to the invention surprisingly prove to be clearly superior to the compounds known from the prior art in their excellent properties in various models in which the antiulcerogenic and the antisecretory properties are determined.
  • the compounds of the formula I and their pharmacologically tolerable salts are outstandingly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of disorders of the stomach and/or intestine.
  • a further subject of the invention is therefore the compounds according to the invention for use in the treatment and/or prophylaxis of the abovementioned diseases.
  • the invention likewise comprises the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the abovementioned diseases.
  • the invention furthermore comprises the use of the compounds according to the invention for the treatment and/or prophylaxis of the abovementioned diseases.
  • a further subject of the invention is medicaments which contain one or more compounds of the formula I and/or their pharmacologically tolerable salts.
  • the medicaments are prepared by methods which are known per se and familiar to the person skilled in the art.
  • a pharmaceutical administration form e.g. a sustained-release form or an enteric-coated form
  • excipients and vehicles which are suitable for the desired pharmaceutical formulations.
  • solvents for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complexing agents (e.g. cyclodextrins).
  • the active compounds can be administered orally, parenterally or percutaneously.
  • the active compound(s) in the case of oral administration in a daily dose of approximately 0.01 to approximately 20, preferably 0.05 to 5, in particular 0.1 to 1.5, mg/kg of body weight, if appropriate in the form of a number, preferably 1 to 4, of individual doses to achieve the desired result.
  • parenteral treatment similar or (in particular in the case of intravenous administration of the active compounds), as a rule, lower doses can be used. Any person skilled in the art can fix the optimum dose and type of administration necessary in each case on the basis of his/her expert knowledge.
  • the pharmaceutical preparation can also contain one or more pharmacologically active constituents of other pharmaceutical groups.
  • tranquilizers for example from the benzodiazepines group, e.g. diazepam
  • spasmolytics e.g. bietamiverine or camylofine
  • anticholinergics e.g. oxyphencyclimine or phencarbamide
  • local anesthetics e.g. tetracaine or procaine
  • enzymes for example from the benzodiazepines group, e.g. diazepam
  • spasmolytics e.g. bietamiverine or camylofine
  • anticholinergics e.g. oxyphencyclimine or phencarbamide
  • local anesthetics e.g. tetracaine or procaine
  • enzymes e.g. tetracaine or procaine
  • H 2 blockers e.g. cimetidine, ranitidine
  • H + /K + ATPase inhibitors e.g. omeprazole, pantoprazole
  • peripheral antcholinergics e.g.
  • pirenzepine pirenzepine, telenzepine
  • gastrin antagonists with the aim of increasing the main action in an additive or superadditive sense and/or eliminating or decreasing the side effects, or furthermore the combination with antibacterially active substances (e.g., for example, cephalosporins, tetracyclines, penicillins, macrolides, nitroimidazoles or otherwise bismuth salts) for the control of Helicobacter pylori .
  • antibacterially active substances e.g., for example, cephalosporins, tetracyclines, penicillins, macrolides, nitroimidazoles or otherwise bismuth salts
  • Antibacterially active combination partners which can be mentioned are, for example, meziocillin, ampicillin, amoxicillin, cefalothin, cefoxitin, cefotaxime, imipenem, gentamycin, amikacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (e.g. clarithromycin+metronidazole).
  • the excellent gastric protective action and the gastric and antisecretory action of the compounds according to the invention can be demonstrated in investigations in animal experimental models.
  • the compounds according to the invention investigated in the model mentioned below have been provided with numbers which correspond to the numbers of these compounds in the examples.
  • the abdomen of anesthetized rates (CD rat, female, 200-250 g; 1.5 g/kg i.m. urethane) was opened after tracheotomy by means of a median upper abdominal incision and a PVC catheter was fixed transorally in the esophagus and another via the pylorus such that the ends of the tubes just projected into the gastric lumen.
  • the catheter leading from the pylorus led outwards into the right abdominal wall through a side opening.
  • the substances to be tested were administered intravenously in 1 ml/kg of liquid volume 60 min after the start of the continuous pentagastrin infusion.
  • the body temperature of the animals was kept at a constant 37.8-38° C. by infrared irradiation and heat pads (automatic, stepless control by means of a rectal temperature sensor).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Saccharide Compounds (AREA)
US09/926,267 1999-04-17 2000-04-14 Haloalkoxy imidazonaphthyridines Expired - Fee Related US6503923B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99107688 1999-04-17
EP99107688 1999-04-17
PCT/EP2000/003388 WO2000063211A1 (en) 1999-04-17 2000-04-14 Haloalkoxy imidazonaphthyridines

Publications (1)

Publication Number Publication Date
US6503923B1 true US6503923B1 (en) 2003-01-07

Family

ID=8237986

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/926,267 Expired - Fee Related US6503923B1 (en) 1999-04-17 2000-04-14 Haloalkoxy imidazonaphthyridines

Country Status (12)

Country Link
US (1) US6503923B1 (de)
EP (1) EP1173439B1 (de)
JP (1) JP2002542248A (de)
AT (1) ATE240956T1 (de)
AU (1) AU3966600A (de)
CA (1) CA2370231A1 (de)
DE (1) DE60002855T2 (de)
DK (1) DK1173439T3 (de)
ES (1) ES2199810T3 (de)
PT (1) PT1173439E (de)
SI (1) SI1173439T1 (de)
WO (1) WO2000063211A1 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106642A1 (en) * 2000-10-25 2004-06-03 Jorg Senn-Bilfinger Polysubstituted imidazopyridines as gastric secretion inhibitors
WO2005077949A1 (en) * 2004-02-17 2005-08-25 Altana Pharma Ag Tricyclic imidazopyridines and intermediates for the synthesis thereof
US20060058836A1 (en) * 2004-09-10 2006-03-16 Arani Bose System and method for treating ischemic stroke
US20060269600A1 (en) * 2002-02-20 2006-11-30 Altana Pharma Ag Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US20080193544A1 (en) * 2005-03-16 2008-08-14 Nycomed Gmbh Taste Masked Dosage Form Containing Roflumilast
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MXPA03007888A (es) * 2001-03-08 2003-12-04 Astrazeneca Ab Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
PL366658A1 (en) 2001-08-02 2005-02-07 Altana Pharma Ag Tricyclic epoxides
BR0211620A (pt) * 2001-08-03 2004-08-24 Altana Pharma Ag Imidazopiridinas substituìdas por alquila para o tratamento de distúrbios gastrointestinais
WO2003014120A1 (en) * 2001-08-03 2003-02-20 Altana Pharma Ag Amino-substituted imidazopyridines for the treatment of gastrointestinal diseases
EA008375B1 (ru) 2002-02-15 2007-04-27 Алтана Фарма Аг Трициклические n-ацильные соединения
MXPA05005117A (es) 2002-11-19 2005-07-01 Altana Pharma Ag Imidazopiridinas 8-sustituidas.
US20060154954A1 (en) * 2003-02-17 2006-07-13 Altana Pharma Ag Combinations and use of selected pharmaceutically active compounds
MXPA05012463A (es) * 2003-05-27 2006-01-30 Altana Pharma Ag Combinaciones farmaceuticas de un inhibidor de bomba protonica y un compuesto que modifica la motilidad gastrointestinal.
CN1874772A (zh) 2003-11-03 2006-12-06 阿斯利康(瑞典)有限公司 治疗隐匿性胃食管反流的咪唑并[1,2－a]吡啶衍生物
AR046893A1 (es) * 2003-12-16 2005-12-28 Altana Pharma Ag Bencimidazoles triciclicos
US7326784B2 (en) 2003-12-19 2008-02-05 Altana Pharma Ag Intermediates for the preparation of tricyclic dihydropyrano-imidazo-pyridines derivatives
WO2006037748A1 (en) * 2004-10-01 2006-04-13 Altana Pharma Ag Substituted tricyclic benzimidazoles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468400A (en) 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
WO1994018199A1 (de) 1993-02-15 1994-08-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
WO1998042707A1 (en) 1997-03-24 1998-10-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyrido compounds
WO2000017200A1 (en) 1998-09-23 2000-03-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468400A (en) 1982-12-20 1984-08-28 Schering Corporation Antiulcer tricyclic imidazo [1,2-a]pyridines
WO1994018199A1 (de) 1993-02-15 1994-08-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
WO1998042707A1 (en) 1997-03-24 1998-10-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyrido compounds
WO2000017200A1 (en) 1998-09-23 2000-03-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869949B2 (en) * 2000-10-25 2005-03-22 Altana Pharma Ag Polysubstituted imidazopyridines as gastric secretion inhibitors
US20040106642A1 (en) * 2000-10-25 2004-06-03 Jorg Senn-Bilfinger Polysubstituted imidazopyridines as gastric secretion inhibitors
US20060269600A1 (en) * 2002-02-20 2006-11-30 Altana Pharma Ag Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US8604064B2 (en) 2003-03-10 2013-12-10 Takeda Gmbh Process for the preparation of roflumilast
US8618142B2 (en) 2003-03-10 2013-12-31 Takeda Gmbh Process for the preparation of roflumilast
WO2005077949A1 (en) * 2004-02-17 2005-08-25 Altana Pharma Ag Tricyclic imidazopyridines and intermediates for the synthesis thereof
US20060058836A1 (en) * 2004-09-10 2006-03-16 Arani Bose System and method for treating ischemic stroke
US8366735B2 (en) 2004-09-10 2013-02-05 Penumbra, Inc. System and method for treating ischemic stroke
US8663694B2 (en) 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
US20080193544A1 (en) * 2005-03-16 2008-08-14 Nycomed Gmbh Taste Masked Dosage Form Containing Roflumilast

Also Published As

Publication number Publication date
ATE240956T1 (de) 2003-06-15
CA2370231A1 (en) 2000-10-26
PT1173439E (pt) 2003-10-31
EP1173439A1 (de) 2002-01-23
EP1173439B1 (de) 2003-05-21
SI1173439T1 (en) 2003-10-31
ES2199810T3 (es) 2004-03-01
AU3966600A (en) 2000-11-02
DE60002855D1 (de) 2003-06-26
DK1173439T3 (da) 2003-09-08
WO2000063211A1 (en) 2000-10-26
DE60002855T2 (de) 2004-05-06
JP2002542248A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
US6503923B1 (en) Haloalkoxy imidazonaphthyridines
CA2156078C (en) New imidazopyridines
US6160119A (en) Fused dihydropyrans
EP0971922B1 (de) Tetrahydropyridoverbindungen
US6916825B2 (en) Alkylated imidazopyridine derivatives
US6384048B1 (en) Imidazonaphthyridines
US7189736B2 (en) Prodrugs of imidazopyridine derivatives
AU740578B2 (en) Tetrahydropyrido compounds
US20080113962A1 (en) Condensed Tricyclic Benzimidazoles For the Treatment of Gastrointestinal Disorders
US6696461B2 (en) Tricyclic imidazopyridines
US6124313A (en) Imidazopyridine azolidinones
US7326718B2 (en) 8-Substituted imidazopyridines
CZ20023210A3 (cs) Pyrano(2,3-)imidazo(-1,2-a)pyridinová sloučenina
AU702166B2 (en) Acylimidazopyridines
AU700737B2 (en) Benzylimidazopyridines
US20080114020A1 (en) Difluoro-Substituted Imidazopyridines
WO2005058893A1 (en) Tricyclic benzimidazoles

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALTANA PHARMA AG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH;REEL/FRAME:013128/0431

Effective date: 20020701

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20110107